ALZHEIMER SOLUTIONS

HOME ABOUT CONTACT RESOURCES RESEARCH
Diagnosis
Stages
Symptoms
Prevention
Treatments
Caregiving
Memory Clinics U.S.
Memory Clinics Canada


References For Alzheimer's Disease Treatments


1. Breitner,JC.et.al.,Delayed onset of alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging, 1995, 16: 523-530.

2. Stewart,W.,et.al., Neurology,1997,48: 626-632.

3. Galli,G.,et.al., Activation of apoptosis by serum deprivation in a teratocarcinoma cell line: inhibition by l-acetylcarnitine. Exp Cell Res, 204: 54-60.

4. Forloni, G.,et.al., Neuroprotective activity of acetyl-l-carnitine: studies in vitro. J Neurosci Res, 1994, 37: 92-96.

5. Passeri,M., et.al., Acetyl-l-carnitine in the treatment of mildly demented elderly patients. Int J Clin Pharmacol Res, 1990, 10: 75-79.

6. Sano,M., et.al., Double blind parallel design pilot study of acetyl levocarnitine in patients with alzheimer's disease. Arch Neurol, 1992, 49: 1137-1141.

7. Spagnoli,A.,et.al., Long term acetyl-l-carnitine treatment in alzheimer's disease. Neurology, 1991, 41:1726-1732.

8. Pettegrew,J.W.,et.al., Clinical and neurochemical effects of acetyl-l-carnitine in alzheimer's disease. Neurobiol Aging, 1995, 16: 1-4.

9. Thal,L.J.,et.al., A l year multicenter placebo-controlled study of acetyl-l-carnitine in patients with alzheimer's disease. Neurology, 1996, 47: 705-711.

10. Brooks, J.O.3rd,et.al., Acetyl-l-carnitine slows decline in younger patients with alzheimer's disease: a reanalysis of a double-blind,placebo-controlled study using the trilinear approach. Int Psychogeriatr, 1998, 10: 193-203.

11. Thal,L.J.,et.al., A 1 year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology, 2000, 55: 805-810.

12. Campi,N., et.al., Selegiline versus acetyl-l-carnitine in the treatment of alzheimer type dementia. Clin Ther, 1990, 12: 306-314.

13. Sinforiano, E.,et.al., Neuropsychological changes in demented patients treated with acetyl-l-carnitine. Int J Clin Pharmacol Res, 1990, 10: 69-74.

14. Deng,Q.S.,et.al., Ionic mechanisms of acupuncture on improvement of learning and memory in aged animals. Am J Chin Med, 1995, 23: 1-9.

15. Chen,Y., Clinical research on treating senile dementia by combining acupunture with acupoint-injection. Acupuncture and Electro Therapeutics Res Int J, 1992, 17: 61-73.

16. Kagan,B.L.,et.al., Oral s-adenosylmethionine in depression: a randomized,double-blind,placebo-controlled trial. Am J Psychiatry, 1990, 147:591-595.

17. Fugh-Berman,A.,et.al., Dietary supplements and natural products as psychotherapeutic agents. Psychosom Med, 1999, 61: 712-728.

18. Cohen,B.M., et.al., S-adenosyl-l-methionine in the treatment of alzheimer's disease. J Clin Psychopharmacol, 1988, 8:43-47.

19. Fritz,C.L., et.al., Association with companion animals and the expression of noncognitive symptoms in alzheimer's patients. J Nerv Ment Dis, 1995, 183: 459-463.

20. Steele,C.,et.al., Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the alzheimer's type: preliminary findings. J Clin Psychiatry, 1986, 47: 310-312.

21. Lemke,M.R.,Effect of carbamazepine on agitation in alzheimer's disease inpatients refractory to neuroleptics. J Clin Psychiatry, 1995, 56: 354-357.

22. Teri,L.,et.al.,Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology, 2000, 55: 1271-1278.

23. Simpson,D.M.,Improvement in organically disturbed behavior with trazodone treatment. J Clin Psychiatry,1996, 47: 191-193.

24. Lebert,F., Behavioral effects of trazodone in alzheimer's disease. J Clin Psychiatry, 1994, 55: 536-538.

25. Gedye,A., Serotonergic treatment for aggression in a Down's syndrome adult showing signs of alzheimer's disease. J Ment Defic Res, 1991,35: 247-258.

26. Feingeld,E.W.,et.al., Double-blind study with phospatidylserine in parkinsonian patients with senile dementia of alzheimer's type. Prog Clin Biol Res, 1989, 317: 1235-1246.

27. Shankle,W.R.,et.al.,Low-dose propanolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord, 1995, 9: 233-237.

28. Amadeo,M.,Antiandrogen treatment of aggressivity in men suffering from dementia. J Geriatr Psychiatry Neurol, 1996, 9: 142-145.

29. Sunderland,T.,Anticholinergic sensitvity in patients with dementia of the alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry, 1987, 44: 418-426.

30. Larson,E.B., Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med, 1987, 107: 169-173.

31. Ames,D.,et.al., Drugs used for psychiatric disorders. Med J Aust, 1993, 159: 116-120.

32. Ames,D.,et.al., Drugs used for psychiatric disorders. Med J Aus, 1993, 159: 116-120.

33. Schneider,L.S., Efficacy of treatment for geropsychiatric patients with severe mental illness. Psychopharmacol Bull, 1993, 29: 501-514.

34. Brooker,D.J.,et.al., Single case evaluation of the effects of aromatherapy and massage on disturbed behavior in severe dementia. Br J Clin Psychol, 1997, 36: 287-296.

35. Rich,J.B.,et.al., Nonsteroidal anti-inflammatory drugs in alzheimer's disease. Neurology, 1995, 45: 51-55.

36. Doraiswamy,P.M.,et.al., NSAIDS and cognition in alzheimer's disease. Neurology, 1996, 46: 1194.

37. Breitner,J.C.,et.al., Delayed onset of alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging, 1995,16: 523-530.

38. Doraiswamy,P.M.,et.al., NSAIDS and cognition in alzheimer's disease. Neurology, 1996, 46: 1194.

39. Inzelberg,R.,et.al.,Effects of atropine on learning and memory functions in dementia. Clin Neuropharmacol,1990,13: 1-7.

40. Preston,G.C.,et.al.,Scopolamine and benzodiazepine models of dementia: cross-reversals by RO 15-1788 and physostigmine. Psychopharmacology, 1989, 98: 487-494.

41. Pomara,N.,et.al., ApoE4 allele and susceptibility to drug-related memory impairment in the elderly. J Clin Psychopharmacol, 1998, 18:179-181.

42. Sobel,B.P., Bingo vs. physical intervention in stimulating short-term cognition in alzheimer's disease patients. Am J Alzheimers Dis Other Dement, 2001, 16: 115-120.

43. Lemke,M.R., Effect of carbamazepine on agitation in alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry, 1995, 56: 354-357.

44. Lemke,M.R.,et.al.,Therapeutic use of carbamazepinefor treatment of agitations and affective disorders in geriatric psychiatry patients. Psychiatr Prax, 1994, 21: 147-150.

45. Marin,D.B.,et.al.,Carbamazepine for aggressive agitation in demented patients. Am J Psychiatry, 1989, 146: 805.

46. Gleason,R.P., et.al., Carbamazepine treatment of agitation in alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry, 1990, 51: 115-118.

47. Raskind,M.A.,et.al., Alzheimer's disease and related disorders. Med Clin North Am,2001, 85: 803-817.

48. Ragneskog,H.,et.al., Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram. Int Psychogeriatr,1996, 8: 659-668.

49. Gottfries,C.G.,et.al., Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. Ann Ny Acad Sci,1991, 640: 276-279.

50. Wu,R.M.,et.al., Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl. Ann Ny Acad Sci, 1996, 786: 379-390.

51. Iwasaki,Y.,et.al., Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons. J Neurol Sci, 1994, 125: 11-13.

52. Martini,E.,et.al., Brief information on an early plase 2 study with deprenyl in demented patients. Pharmacopsychiatry, 1987, 20: 256-257.

53. Tariot,P.N.,et.al., Cognitive effects of l-deprenyl in alzheimer's disease. Psychopharmacology, 1987, 91: 489-495.

54. Schneider,L.S., et.al., A pilot study of low dose l-deprenyl in alzheimer's disease. J Geriatr Psychiatry Neurol, 1991, 4: 143-148.

55. Burke,W.J.,et.al., L-deprenyl in the treatment of mild dementia of the alzheimer type: results of a 15 month trial. J Am Geriatr Soc, 1993, 41: 1219-1225.

56. Freedman,M.,et.al., L-deprenyl in alzheimer's disease: cognitive and behavioral effects. Neurology,1998, 50: 660-668.

57. Shepherd,J.E., Effects of estrogen on cognition,mood, and degenerative brain diseases. J Am Pharm Assoc, 2001, 41: 221-228.

58. Greene,R.A., Estrogen and cerebral blood flow: a mechanism to explain the impact of estrogen on the incidence and treatment of alzheimer's disease. Int J Fertil Womens Med, 2000, 45: 153-257.

59. Panidis,D.K.,et.al., The role of estrogen replacement therapy in alzheimer's disease. Eur J Obstet Gynecol Reprod Biol, 2001, 95: 86-91.

60. Greene,R.A., Estrogen and cerebral blood flow: a mechanism to explain the impact of estrogen on the incidence and treatment of alzheimer's disease. Int J Fertil Womens Med, 2000, 45: 153-257.

61. Kim,H.,et.al., Neuroprotective effects of estrogen against beta-amyloid toxicity are mediated by estrogen receptors in cultured neuronal cells. Neurosci Lett, 2001, 302: 58-62.

62. Li,R.,et.al., Estrogen enhances the uptake of amyloid beta protein by microglia derived from the human cortex. J Neurochem, 2000, 75: 1447-1454.

63. Kampen,D.L.,et.al., Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol, 1994, 83: 979-983.

64. Robinson,D.,et.al., Estrogen replacement therapy and memory in olders women. J Am Geriatr Soc, 1994, 12: 919-922.

65. Ohkura,T.,et.al., Long-term estrogen replacement therapy in female patients with dementia of the alzheimer type: 7 case reports. Dementia, 1995, 6: 99-107.

66. Schneider,L.S., et.al., Effects of estrogen replacement therapy on response to tacrine in patients with alzheimer's disease. Neurology, 1996, 46: 1580-1584.

67. Olichney,J.M.,et.al., Estrogen use and decline in cognition among alzheimer's disease patients. Neurology, 1999, 52: A 395.

68. Relkin,N.,et.al., The effect of concomitant donepezil and estrogen treatment on the cognitive performance of women with alzheimer's disease. Neurology,1999, 52: A397.

69. Kyomen,H.H.,et.al., The use of estrogen to decrease aggressive physical behavior in elderly men with dementia. J Am Geriatr Soc, 39:1110-1112.

70. Kay,P.A., et.al., Transdermal estradiol in the management of aggressive behaviors in male patients with dementia. Clin Gerontologist, 1995, 15: 54-58.

71. Kondo,K., et.al., A case-control study of alzheimer's disease in Japan- significance of life styles. Dementia, 1994, 5: 314-326.

72. Broe,G.A.,et.al., A case-control study of alzheimer's disease in Australia. Neurology,1990, 40: 1698-1707.

73. Shimamura,K.,et.al., Environmental factors possibly associated with onset of senile dementia. Nippon Koshu Eisei Zasshi,1998, 45: 203-212.

74. Okamoto,K.,et.al., Sociomedical and lifestyle risk factors of senile dementia,determined in a nested case-control study. Nippon Ronen Igakkai Zasshi, 1994,31: 604-609.

75. Rolland,Y.,et.al.,Feasibility of regular physical exercise for patients with moderate to severe alzheimer disease. J Nutr Health Aging, 2000, 4: 109-113.

76. Lindemuth,G.F.,et.al., Improving cognitive abilites of elderly alzheimer's patients with intense exercise therapy. Am J Alzheimer's Care Rel Dis Res, 1990,5: 31-33.

77. Namaxzi,K.H., et.al., A low intensity exercise/movement program for patients with alzheimer's disease: the TEMP-AD protocol. J Aging Phys Act,1994, 2: 80-92.

78. Friedman,R.,et.al., The effects of planned walking on communication in alzheimer's disease. J Am Geriatr Soc, 1991, 39: 650-654.

79. Roane,D.M., et.al., Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci, 2000, 12: 40-43.

80. Herrmann, N.,et.al., Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol, 2000, 20: 90-93.

81. Hawkins,J.W.,et.al., A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementia. Am J Geriatr Psychiatry, 2000, 8: 221-225.

82. Maurer,K.,et.al., Clinical efficacy of gingko biloba extract EGb 761 in dementia of the alzheimer type. J Psychiatry Res, 1997, 31: 645-655.

83. Wettstein,A., Cholinesterase inhibitors and gingko extracts-- are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine, 2000, 6: 393-401.

84. Le Bars, P.L., et.al., A 26-week analysis of a double-blind, placebo-controlled trial of the gingko biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord, 2000, 11: 230-237.

85. Le Bars,P.L., et.al., A placebo-controlled,double-blind, randomized trial of an extract of gingko biloba for dementia. JAMA, 1997, 278: 1327-1332.

86. Haase,J.,et.al., Effectiveness of brief infusions with gingko biloba extracts EGb 716 in dementia of the vascular and alzheimer type. Z Gerontol Geriatr, 1996, 29: 302-309.

87. Thomson,G.J., et.al., A clinical trial of gingko biloba extract in patients with intermittent claudication. Int Angiol, 1990, 9: 75-78.

88. Yao,Z., et.al., The gingko biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid induced cell death by inhibiting the formation of beta amyloid diffusible neurotoxic ligands. Brain Res, 2001, 889: 181-190.

89. Itil, T.M., et.al., The pharmacological effects of gingko biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull, 1998, 34: 391-397.

90. Cheng, D.H.,et.al., Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport, 1996, 8: 97-101.

91. Zhu, X.Z., et.al., Development of natural products as drugs acting on central nervous system. Mem Inst Oswaldo Cruz, 1991, 86: 173-175.

92. Skolnick,A.A., Old chinese herbal medicine used for fever yields possible new alzheimer disease therapy. JAMA, 1997, 277: 776.

93. Sun,Q.Q.,et.al., Huperzine A capsules enhance memory and learning peformance in 34 pairs of matched adolescent students. Zhongguo Yao Li Xue Bao, 1999, 20: 601-603.

94. Xu,S.S., et.al., Efficacy of tablet huperzine A on memory,cognition,and behavior in alzheimer's disease. Zhongguo Yao Li Xue Bao, 1995, 16: 391-395.

95. Zhang,H.Y., et.al., Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC 12 cells. Neurosci Lett, 2000, 292: 41-44.

96. Xiao,X.Q.,et.al., Huperzine A and tacrine attenuate beta-amyloid induced oxidative injury. J Neurosci Res, 2000, 61: 564-569.

97. Breitner,J.C., et.al., Delayed onset of alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging, 1995, 16: 523-530.

98. Corrada,M., et.al., Nonsteroidal anti-inflammatory drugs and the risk of alzheimer's disease. Neurology, 1996, 46: A433.

99. Lambat,Z., et.al., An investigation into the neuroprotective properties of ibuprofen. Metab Brain Dis, 2000, 15: 249- 256.

100. Lim,G.P., et.al., Ibuprofen suppresses plaque pathology and inflammation in a mouse model for alzheimer's disease. J Neurosci Res, 2000, 20: 5709-5714.

101. Rogers,J., et.al., Clinical trials of indomethacin in alzheimer's disease. Neurology, 1993, 43: 1609-1611.

102. Lockhart,B.P., et.al., Inhibitors of free radical formation fail to attenuate direct beta-amyloid 25-35 peptide mediated neurotoxicity in rat hippocampal cultures. J Neurosci Res, 1994, 39: 494-505.

103. Goodman, Y., et.al., Nordihydroquiacetic acid protects hippocampal neurons against amyloid beta peptide toxicity and attenuates free radical and calcium accumulation. Brain Res, 1994, 654: 171-176.

104. Netland,E.E., et.al., Indomethacin reverses the microglial response to amyloid beta protein. Neurobiol Aging, 1998, 19: 201-204.

105. Mallet,L., et.al., Indomethacin-induced behavioral changes in an elderly patient with dementia. Annals of Pharmacotherapy,1998, 32: 201-203.

106. Higgins, J.P.T., et.al., Lecithin for dementia and cognitive impairment. Cochrane Library, 2001, 2: Oxford.

107. Otsuka,A.,et.al., Absence of nocturnal fall in blood pressure in elderly persons with alzheimer type dementia. J Am Geriatr Soc, 1990, 38: 973-978.

108. Otsuka,A., et.al., Circadian changes of blood pressure in the elderly with alzheimer's type dementia. Nippon Ronen Igakkai Zaashi, 1990, 27: 570-572.

109. Reynolds,V.,et.al., Heart rate variation, age, and behavior in patients with senile dementia of alzheimer type. Chronobiol Int, 1995, 12: 37-45.

110. Tate,B., et.al., Disruption of circadian regulation by brain grafts that overexpress alzheimer amyloid beta protein. Proc Natl Acad Sci USA, 1992, 89: 7090-7094.

111. Swaab,D.F., et.al., The suprachiasmatic nucleus in the human brain in relation to age,sex, and senile dementia. Brain Res, 1985, 342: 37-44.

112. Mishima,K.,et.al., Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand, 1994, 89: 1-7.

113. Lovell,B.B.,et.al., Effect of bright light treatment on agitated behavior in institutionalized elderly subjects. J Psychiatry Res, 1995, 57: 7-12.

114. Ito,T., et.al., Effects of bright light on cognitive disturbances in alzheimer-type dementia. Nippon Ika Daigaku Zaashi, 1999, 66: 229-238.

115. Campbell,S.S., et.al., Exposure to light in healthy elderly subjects and alzheimer's patients. Physiol Behav, 1988, 42: 141-144.

116. Brinkman,S.D., et.al., Lithium-induced increases in red blood cell choline and memory performance in alzheimer-type dementia. Biol Psychiatry, 1984, 19: 157-164.

117. Pomara,N., et.al., Elevation of red blood cell glycine and choline levels in geriatric patients treated with lithium. Am J Psychiatry, 1983, 140: 911-913.

118. Randels,P.M., et.al., Lithium and lecithin treatment in alzheimer's disease: a pilot study. Hillside J Clin Psychiatry, 1984, 6: 139-147.

119. Kelwala,S.,et.al., Lithium-induced accentuation of extrapyramidal symptoms in individuals with alzheimer's disease. J Clin Psychiatry, 1984, 45: 343-344.

120. Brinkman,S.D., et.al., Lithium induced increases in red blood cell choline and memory performance in alzheimer type dementia. Biol Psychiatry, 1984, 19: 157-164.

121. Rowe,M., et.al., The effectiveness of slow-stroke massage in diffusing agitated behaviors in individuals with alzheimer's disease. J Gerontol Nursing, 1999, 25: 22-34.

122. Lord,T.R., et.al., Effects of music on alzheimer patients. Percept Mot Skills, 1993, 76: 451-455.

123. Casby,J.A.,et.al., The effect of music on repetitive disruptive vocalizations of persons with dementia. Am J Occup Ther, 1994, 48: 883-889.

124. Gerdner,L.A., Effects of individualized versus classical relaxation music on the frequency of agitation in elderly persons with alzheimer's disease and related disorders. Int Psychogeriatr, 2000, 12: 49-65.

125. Aldrige,D., Alzheimer's disease: rhythm,timing,and music as therapy. Biomed Pharmacother, 1994, 48: 275-281.

126. Hasegawa,Y., et.al., Music therapy induced alterations in natural killer cell count and function. Nippon Ronen Iggakai Zaashi, 2001, 38: 201-204.

127. Cattan,R., et.al., Music therapy increases serum melatonin levels in patients with alzheimer's disease. Altern Ther Health Med, 1999, 5: 49-57.

128. Birkmayer,J.G., et.al., Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the alzheimer type. Ann Clin Lab Sci, 1996, 26: 1-9.

129. Lapchak,P.A., et.al., Effect of recombinant human nerve growth factor on presynaptic cholinergic function in rat hippocampal slices following partial septohippocampal lesions: measures of acetylcholine synthesis, acetycholine release,and choline acetyltransferase activity. Neurocience, 1991, 42: 639-649.

130. Castro,M., et.al., Does the Kunitz domain from the alzheimer's amyloid beta protein precursor inhibit a kallikrein responsible for post-translational processing of nerve growth factor precursor? FEBS Lett,1990, 267: 207-212.

131. Olson,L., Grafts and growth factors in CNS. Basic science with clinical promise. Stereotact Funct Neurosurg,1990, 54-55: 250-267.

132. Eriksdotter,M.,et.al.,Intracerebroventricular infusion of nerve growth factor in three patients with alzheimer's disease. Dement Geriatr Cogn Disord, 1998, 9: 246-257.

133. Shalat,S.L., et.al., Risk factors for alzheimer's disease: a case-control study. Neurology, 1987, 37: 1630-1633.

134. Wang,P.N., et.al., Risk factors for alzheimer's disease: a case-control study. Neuroepidemiology, 1997, 16: 234-240.

135. Ott,A., et.al., Smoking and the risk of dementia and alzheimer's disease in a population-based cohort study: The Rotterdam Study. Lancet, 1998, 351: 1840-1843.

136. Lee,P.N., et.al., Smoking and alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology, 1994, 13: 131-144.

137. Snaedal,J., et.al., The effects of nicotine in dermal plaster on cognitive function in patients with alzheimer's disease. Dementia, 1996, 7: 47-52.

138. White,H.K., et.al., Four week trial of nicotine skin patch treatment effects on cognitive performance in alzheimer's disease. Psychopharmacology, 1999, 143: 158-165.

139. Raskind,M.A., et.al., Alzheimer's disease and related disorders. Med Clin North Am, 2001, 85: 803-817.

140. Street,J.S., et.al., Olanzapine treatment of psychotic and behavioral symptoms in patients with alzheimer disease in nursing care facilities: a double-blind, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry, 2000, 57: 968-976.

141. Jacobs,E.A., et.al., Hyperoxygenation effect on cognitive functioning in the aged. New England J Medicine, 1969, 281: 753-757.

142. Fraiberg,P.L., Oxygen inhalation in the control of psychogeriatric symptoms in patients with long- term illness. J Am Geriatr Soc, 1973, 21: 321-328.

143. Goldfarb,A.I., et.al., Hyperbaric oxygen treatment of organic mental syndrome in aged persons. J Gerontol, 1972, 27: 212.

144. Ben-Vishay,Y., et.al., Can oxygen reverse symptoms of senility? NY State J Med, 1978, 78: 914-919.

145. Holdsworth,F., Hyperbaric oxygen and senile psychosis. Lancet, 1969, 2: 1340.

146. Delwaide,P.J., et.al.,Double-blind, randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand, 1986, 73: 136-140.

147. Schreiber, S., et.al., An open trial of plant-source derived phosphatidylserine for treatment of age-related cognitive decline. Isr J Psychiatry Relat Sci, 2000, 37: 302-307.

148. Crook,T.,et.al., Effects of phosphatidylserine in alzheimer's disease. Psychopharmacol Bull, 1992, 28: 61-66.

149. Funfgeld,E.W., et.al., Double-blind study with phosphatidylserine in parkisonian patients with senile dementia of alzheimer's type. Prog Clin Biol Res, 1989, 317: 1235-1246.

150. Naor,S., et.al., Phosphatidylserine effect on functioning and general condition of alzheimer's disease patients. J Am Geriatr Soc, 1998, 46: S100.

151. Sandoz,C.J.,et.al.,Photographs as a tool in memory preservation for patients with alzheimer's disease. Clinical Gerontologist, 1996, 17: 69-71.

152. Johansson,M.,et.al., Pharmacokinetic studies of cholinesterase inhibitors. Acta Neurol Scand, 1993, 149: 22-25.

153. Caltagirone,C.,et.al., Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in alzheimer's presenile dementia. Int J Neurosci,1982,16: 247-249.

154. Jenike,M.A., et.al., Oral physostigmine as treatment for primary degenerative dementia: a double-blind, placebo-controlled inpatient trial. J Geriatr Psychiatry, 1990, 3: 13-16.

155. Stern,Y., et.al., Long-term administration of oral physostigmine in alzheimer's disease. Neurology, 1988, 38: 1837-1841.

156. Mohs,R.C.,et.al., Clinical studies of the cholinergic deficit in alzheimer's disease. J Am Geriatr Soc, 1985, 33: 749-757.

157. Schwartz,A.S., et.al., Physostigmine effects in alzheimer's disease: realtionship to dementia severity. Life Sci, 1986, 38: 1021-1028.

158. Levy,A., et.al., Transdermal physostigmine in the treatment of alzheimer's disease. Alzheimer Dis Assoc Disord, 1994, 8: 15-21.

159. Gustafson,L., Physostigmine and tetrahydroaminoacridine treatment of alzheimer's disease. Acta Neurol Scand, 1993, 149: 39-41.

160. Stoppe,G.,et.al., Prescribing practice with cognition enhancers in outpatient care: are there differences regarding types of dementia?--Results of a representitive survey in Saxony,Germany. Pharmacopsychiatry, 1996, 29: 150-155.

161. Flicker,L., et.al., Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev,2001, 2: CD001011.

162. Pierlovisi-Lavaivre,M.,et.al., The significance of quantified EEG in alzheimer's disease. Changes induced by piracetam. Neurophysiol Clin, 1991,21: 411-423.

163. Pauszek,M.E., Propanolol for treatment of agitation in senile dementia. Indiana Med, 1991, 84: 16-17.

164. Weiler,P.G., et.al., Propanolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol, 1988, 1: 226-230.

165. Shankle,W.R.,et.al., Low-dose propanolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord, 1995, 9: 233-237.

166. Rother,M.,et.al., Propentofylline in the treatment of alzheimer's disease and vascular dementia: a review of phase 3 trials. Dement Geriatr Cogn Disord, 1998, 9: 36-43.

167. Mielke,R., et.al., Propentofylline enhances cerebral metabolic response to auditory memory stimulation in alzheimers. J Neurol Sci, 1998, 154: 76-82.

168. Marcusson,J., et.al., A 12 month, randomized,placebo-controlled trial of propentofylline in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord, 1997, 8: 320-328.

169. Bachynsky,J., et.al., Propentofylline treatment for alzheimer disease and vascular dementia: an economic evaluation based on functional abilities. Alzheimer Dis Assoc Disord, 2000, 2: 102-111.

170. Mielke,R., et.al., Propentofylline in the treatment of vascular dementia and alzheimer-type dementia: overview of phase 1and phase 2 clinical trials. Alzheimer Dis Assoc Disord, 1998, 12:Suppl, S29-S35.

171. McRae,A., et.al., Propentofylline depresses amyloid and alzheimer's CSF microglial antigens after ischemia. Neuroreport, 1994, 5: 1193-1196.

172. Koriyama,Y.,et.al., Evaluation of neurotoxicity of alzheimer's amyloid beta protein in cultured hippocampal cells and its prevention by propentofylline. Jpn J Pharmacol, 2000, 82: 301-306.

173. Nabeshima,T., Nerve growth factor strategy and preparation of animal model for alzheimer-type senile dementia. Yakugaku Zaashi, 1995, 115: 499-512.

174. Frenchman,I.B.,et.al., Clinical experience with risperidone,haloperidol,and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr, 1997, 9: 431-435.

175. Claus,A., et.al., Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta Psychiatr Scand, 1992, 85: 295-305.

176. Lopez,I., et.al., Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol. Actas Luso Esp Neurol Psiquiatr Cienc Afines, 1996, 24: 165-172.

177. Raheja,R.K., et.al.,Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. J Geriatr Psychiatr Neurol, 1995, 8: 159-161.

178. Goldberg,R.J., et.al., Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr,1997, 9: 65-68.

179. Barcia,D., et.al., Risperidone in the treatment of psychotic,affective and behavioral symptoms associated to alzheimer's disease. Actas Esp Psiquiatr, 1999, 27: 185-190.

180. Katz,I.R., et.al., Comparison of risperidone and placebo for psychosisand behavioral disturbances associated with dementia: a randomized,double-blind trial. J Clin Psychiatry,1999, 60: 107-115.

181. Christensen,H., et.al., Cholinergic blockade as a model of the cognitive deficits in alzheimer's disease. Brain, 1992, 115: 1681-1699.

182. Rabey,J.M., et.al., Cognitive effects of scopolamine in dementia. J Neural Transm Gen Sect, 1996, 103: 873-881.

183. Sunderland,T., et.al., Anticholinergic sensitivity in patients with dementia of the alzheimer type and age-matched controls, A dose-response study. Arch Gen Psychiatry, 1987, 44: 418-426.

184. Krieger,J., Sleep apneas. Rev Med Interne, 1994, 15: 460-470.

185. Pressman,M.R., et.al., Nocturia: A rarely recognized symptom of sleep apnea and other occult sleep disorders. Arch Intern Med, 1996, 156: 545-550.

186. Hudgel,D.W., Neuropsychiatric manifestations of obstructive sleep apnea: a review. Int J Psycjiatry Med, 1989, 19: 11-22.

187. Yesavage,J., et.al., Preliminary communication: intellectual deficit and sleep-related respiratory disturbance in the elderly. Sleep, 1985, 8: 30-33.

188. Kaluza,C.L., et.al., Obstructive sleep apnea: a multisystemic disorder. J Am Osteopath Assoc, 1995, 95: 420-426.

189. Guilleminault,C., Obstructive sleep apnea syndrome: a review. Psychiatr Clin North Am,1987, 10: 607-621.

190. Hoch,C.C., et.al., Electroencephalographic sleep in late-life neuropsychiatric disorders. Int Psychogeriatr, 1989, 1: 51-62.

191. Erkinjuntti,T., et.al., Sleep apnea in multiinfarct dementia and alzheimer's disease. Sleep, 1987, 10: 419-425.

192. Hoch,C.C., et.al., Sleep-disordered breathing in normal and pathologic aging. J Clin Psychiatry, 1986, 47: 499-503.

193. Erkinjuntti,T., et.al., Snoring and dementia. Age Ageing, 1987, 16: 305-310.

194. Keenan,P.A., et.al., The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology, 1996, 47: 13896-1402.

195. Varney,N.R., et.al., Reversible steroid dementia in patients without steroid psychosis. Am J Psychiatry, 1984, 141: 369-372.

196. Aisen,P.S., et.al., A randomized controlled trial of prednisone in alzheimer's disease. Neurology, 2000, 54: 588-593.

197. Chynoweth,R., et.al., Pre-senile dementia responding to steroid therapy. Brit J Psychiatry, 1969, 115: 703-708.

198. Paulson,G.W., Steroid-sensitive dementia. Am J Psychiatry, 1983, 140: 1031-1033.

199. Griffin,R.L., et.al., An overview of therapeutic touch and its application to patients with alzheimer's disease. Am J Alzheimer Dis, July-August,1998, 211-215.

200. Gold,M., et.al., Plasma thiamine deficiency asscoiated with alzheimer's disease but not Parkinson's disease. Metab Brain Dis, 1998, 13: 43-53.

201. Watkins,S.E., et.al., Plasma amino acids in patients with senile dementia and in subjects with Down's syndrome at an age vulnerable to alzheimer changes. J Ment Defic Res, 1989, 33: 159-166.

202. Blass,J.P., et.al., Thiamine and alzheimer's disease. Arch Neurol, 1988, 45: 833-835.

203. Meador,K., et.al., Preliminary findings of high-dose thiamine in dementia of alzheimer's type. J Geriatr Psychiatry Neurol, 1993, 6: 222-229.

204. Nolan,K.A., et.al., A trial of thiamine in alzheimer's disease. Arch Neurol, 1991, 48: 81-83.

205. Sandyk,R., Alzheimer's disease: improvement of visual memory and visuoconstructive performance by treatment with picotesla range magnetic fields. Int J Neurosci, 1994, 76: 183-225.

206. Sherder,E.J., et.al., Effects of transcutaneous electrical nerve stimulation on memoryand behavior in alzheimer's disease may be stage-dependent. Biol Psychiatry, 1999, 45: 743-749.

207. Sherder,E.J., et.al., Peripheral nerve stimulation in alzheimer's disease. Tijdschr Gerontol Geriatr, 1997, 28: 59-68.

208. Lebert,F., et.al., Behavioral effects of trazodone in alzheimer's disease. J Clin Psychiatry, 1994, 55: 536-538.

209. Sultzer,D.L., et.al., A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry, 1997,5: 60-69.

210. Walsh,A.C., Arterial insufficiency of the brain: progression prevented by long-term anticoagulant therapy in eleven patients. J Am Geriatr Soc, 1969, 17: 93-104.

211. Walsh,A.C., et.al., Senile and presenile dementia: further observations on the benefits of a dicumarol-psychotherapy regimen. J Am Geriatr Soc, 1972, 20: 127-131.

212. Walsh,A.C., Anticoagulant therapy for dementia: informed consent. J Neuropsychiatry Clin Neurosci, 1992, 4: 463.

213. Walsh,A.C., Anticoagulant therapy for dementia. J Neuropsychiatry Clin Neurosci, 1995,7: 119.

214. Ratner,J., et.al.,Anticoagulant therapy for senile dementia.J Amer Geriatric Soc., 1972, 20: 556-559.

215. Langtry,H.D., et.al., Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs, 1990, 40: 291-313.

216. Scharf,M.B., et.al., Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry, 1991, 52: 77-83.

217. Jackson,C.W., et.al., Zolpidem for the treatment of agitation in elderly demented patients. J Clin Psychiatry,1996, 57: 372.

218. Shelton,P.S., et.al., Zolpidem for dementia-related insomnia and nightime wandering. Ann Pharmacother, 1997,31: 319-322.

219. Hoehns,J.D., et.al., Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm, 1993, 12: 814-828.